Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APOB | P04114 | 4/20 | 0.46 |
| ▸ | MTTP | P55157 | 4/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293472 | 0.95 | NTRK1 (0.51) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3288509 | 0.95 | NTRK1 (0.50) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3291768 | 0.95 | NTRK1 (0.50) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3288520 | 0.93 | NTRK1 (0.49) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL4074904 | 0.93 | EPHX2 (0.49) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3295229 | 0.93 | NPC1 (0.50) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3290024 | 0.93 | NTRK1 (0.48) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3290110 | 0.93 | NTRK1 (0.48) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL13329048 | 0.92 | APOB (0.47) | NTRK1KCNH2NTRK3NTRK2EPHX2 | |
| SCHEMBL3292493 | 0.91 | POLB (0.51) | NTRK1KCNH2NTRK3NTRK2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | NTRK1 3143/4885KCNH2 590/4885NTRK3 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.